This study is for adult men and postmenopausal women with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer. You may be eligible if your cancer has a change in the PI3K pathway, such as a PIK3CA mutation, PTEN loss, or AKT1 mutation. The study is testing the safety and effectiveness of a combination of three drugs: evexomostat, plus either alpelisib or capivasertib, and fulvestrant. Researchers want to see how well this "triplet therapy" works to shrink tumors and how many patients experience high blood sugar (hyperglycemia), which can be a side effect of some of these drugs. The study aims to understand the side effects and benefits of this new combination.

Study design

This is an open-label study, meaning you and your doctors will know which treatment you are receiving. It plans to enroll 52 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your health will be monitored for side effects for up to 48 months, and for high blood sugar events for up to 42 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.